Hepatitis C Therapy - Anadys travels a different path

Anadys travels a different path
SignOn San Diego - In a heady year for patients seeking significant advances in the treatment of hepatitis C, San Diego's Anadys Pharmaceuticals has been not so much overlooked as overshadowed. Most of the attention has focused on biotech companies developing new drugs

SciClone Reports Results From First ZADAXIN Phase 3 Hepatitis C Trial
Market Wire - SAN MATEO, CA -- (MARKET WIRE) -- 12/14/2005 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ) today announced top-line results from the first of its two phase 3 clinical trials using ZADAXIN (thymalfasin) in combination with pegylated interferon

Higher doses of pegylated interferon or ribavirin improve hepatitis C
Aidsmap - Given that standard hepatitis C therapy with pegylated interferon plus ribavirin produces a sustained virological response (SVR) in less than 50% in patients with genotype 1 hepatitis C, researchers are continually seeking ways to improve response

Vertex hepatitis C drug gets fast track
WRGB - (Cambridge, MASS - AP) Vertex Pharmaceuticals has received a "fast track" designation from regulators for a hepatitis C therapy they're developing. The Cambridge-based company's shares rose more than two-percent 56 cents, or 2.2 percent in early